Fig. 6: Systemic delivery of AAV9-iNG improved histopathology and contractility in mdx4cv mice.
From: Efficient precise in vivo base editing in adult dystrophic mice
a Trichrome staining of muscle and heart sections showing the extensive fibrosis in diaphragm and gastrocnemius (GA) muscles of mdx4cv mice (10 months of age). The mdx4cv mouse heart had little fibrosis at 10 months of age. Scale bar: 200 µm. b–d Quantification of fibrotic area of the diaphragm, gastrocnemius and heart muscles. n = 3 WT, 4 mdx4cv and 4 AAV9-iNG treated mice. ns not significant; one-way ANOVA with Turkey’s multiple comparisons test. Data are mean ± SD. e–h Measurement of CNF in the diaphragm (e, f) and gastrocnemius (g, h) muscles of mdx4cv mice with or without AAV9-iNG treatment at 10 weeks (n = 7 untreated and 5 treated mice, (e, g) or 10 months (n = 4 mice/group, f, h) of age (two-tailed unpaired t test). Data are mean ± SD. i–l Muscle fiber size measurement and distribution in diaphragm and gastrocnemius muscles of the mice (n = 3 WT, 4 mdx4cv and 5 AAV9-iNG treated) at 10 weeks of age. ns not significant; one-way ANOVA with Turkey’s multiple comparisons test. Data are mean ± SD. m Tetanic torque measurements of the posterior compartment muscles of the mice (n = 8 WT, 9 mdx4cv and 5 AAV9-iNG treated; one-way ANOVA with Turkey’s multiple comparisons test). Data are mean ± SD.
